LAS VEGAS, June 28, 2012 (GLOBE NEWSWIRE) -- Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI) today announced the successful completion of two new studies undertaken for DermSafe®, a non-alcohol hand sanitizer made with 4% Chlorhexidine Gluconate. The studies demonstrate the sustained (up to 4 hours) and potent killing of both gram-negative and gram-positive bacteria by DermSafe.
The studies proved the persistent ability of DermSafe on two different bacteria. This evaluation was based on ASTM 2752-10 Standard Guide for Evaluation of Residual Effectiveness of Antibacterial Personal Cleansing Products. The studies conducted by Bioscience Laboratories showed the difference between the number of challenge bacterial species recovered following exposure to the treated forearm skin of subjects and the number of bacteria recovered following exposure to untreated skin (control) from 1 hour and up to 4 hours following application of DermSafe.
The initial study tested DermSafe against Methicillin-resistant Staphylococcus aureus or MRSA (ATCC #33591), a "super bug" which is very prevalent in the community including hospital environments. The test results showed that DermSafe tested at 1 hour, 2 hours and 4 hours dramatically reduced MRSA with a kill of 93.39% at 4 hours. Even when the test sites were rinsed prior to each bacteria challenge, the test results showed a 95.83% reduction at the 4 hour time point.
The findings of the second study verified DermSafe's potent and increasing activity against Escherichia coli or E. coli (ATCC #43888") at both 2 and 4 hours with a 99.38% reduction at 4 hours.
"We are pleased with these new study results which solidify our previous studies conducted on DermSafe formulated with our patented Invisicare® technology. This new in-vivo data confirms the excellent persistency and efficacy profile of DermSafe", stated Mr. Terry Howlett, President and CEO. "We believe these new studies will benefit our licensees in both Canada and Europe in facilitating the marketing of DermSafe not only to the general public but for commercial use in hospitals, schools, law enforcement and the military ."
DermSafe is currently available from Alto Pharmaceuticals in Canada. Skinvisible is seeking additional licensees in select territories for commercial and/or retail markets.
About Skinvisible Pharmaceuticals, Inc
Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing irritation. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. Skinvisible's value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. www.skinvisible.com and www.invisicare.com.
The Skinvisible, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7744
Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10K for the year ending December 31, 2011).
CONTACT: Corporate Contact: Doreen McMorran Skinvisible Pharmaceuticals, Inc. Phone: 702-433-7154 Email: firstname.lastname@example.org